Left Atrial Appendage Closure With Versus Without Pulsed Field Ablation in Atrial Fibrillation Patients With Mild Symptoms and High Stroke Risk

NCT07453940 · tracked via the Priya Life Science China tracker

Sponsor

Sir Run Run Shaw Hospital

Phase

Not applicable

Started

2026-05-07

Last updated

2026-07-01

Condition(s) studied

ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATIONPFA Ablation and LAAC Procedures

Investigational drug(s) / intervention(s)

LAAC plus PFA for persistent AF with high risk of strokeLAAC for persistent AF with high risk of stroke

LAAC plus PFA for persistent AF with high risk of stroke: Pulmonary vein isolation (PVI) and posterior wall isolation (PWI) will be performed using the FARAPULSE system, then LAAC will be done. If sinus rhythm could not be restored after PFA, cardioversion will be performed. Additional ablation is allowed only if a clear arrhythmia mechanism is identified; empirical ablation is prohibited.

LAAC for persistent AF with high risk of stroke: Patients will undergo electrical cardioversion followed by LAAC under general anesthesia; if sinus rhythm could not be achieved by the end of procedure, pharmocol cardioversion will be tried to restore it.

Study summary

This study is a prospective, multicenter, single-blinded, randomized controlled trial to investigate whether concomitant left atrial appendage closure (LAAC) and pulsed field ablation (PFA) is more effective than LAAC alone in improving the outcomes in persistent atrial fibrillation (AF) patients with high risk of stroke.

Emerging data show that some-especially those with persistent AF, high AF burden, or early atrial re-modelling-have high stroke and heart failure risks. This pilot study aims to assess whether combining LAAC and PFA improves outcomes more than LAAC alone in persistent AF patients at high stroke risk. Fifty participants will be randomly assigned in a 1:1 ratio to the LAAC or LAAC plus PFA group, with group allocation blinded.

Baseline assessments included cardiopulmonary exercise testing (CPET), the Atrial Fibrillation Effect on QualiTy-of-life questionnaire (AFEQT) , and brain magnetic resonance imaging (MRI). In the LAAC group, patients will undergo electrical cardioversion followed by LAAC under general anesthesia; if sinus rhythm could not be achieved by the end of procedure, pharmocol cardioversion will be tried to restore it. In the LAAC plus PFA group, pulmonary vein isolation (PVI) and posterior wall isolation (PWI) will be performed using the FARAPULSE system, then LAAC will be done. If sinus rhythm could not be restored after PFA, cardioversion will be performed. Additional ablation is allowed only if a clear arrhythmia mechanism is identified; empirical ablation is prohibited. Follow-up occurs every two months with 7-day Holter monitoring. CPET, AFEQT, and brain MRI will be repeated at 6 months. During the blanking period, antiarrhythmic drugs may be used except amiodarone due to its long half-life. Ablation is not recommended within the first two months. Crossover to ablation is permitted only for patients with documented AF/AFL/AT recurrence and worsened symptoms (AFEQT score drop ≥10 points from baseline). At crossover or redo-ablation, AFEQT, CPET, and brain MRI will be repeated.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Age ≥ 18 years old. 2. Subjects diagnosed with persistent AF with duration more than 3 months. 3. Subjects with AFEQT score \>70 . 4. Subjects with CHA2DS2-VA score ≥2. 5. Subjects who are willing and capable of providing ICF and participating in all testing associated with this study. Exclusion Criteria: 1. AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible/non-cardiac causes. 2. Subjects with the history of AF ablation, LAA surgically closed or otherwise excluded or the LAA anatomy does not accommodate a Closure Device. 3. Left atrial anteroposterior diameter ≥ 5.5 cm. 4. Heart failure with a NYHA III/IV and/or LVEF ≤35% within 3 months prior to the procedure. 5. Any of the following events within 90 days of the Consent Date: * Myocardial infarction, unstable angina or coronary intervention or any cardiac surgery * Pericarditis or symptomatic pericardial effusion * Gastrointestinal bleeding * Stroke, TIA, or intracranial bleeding or any non-neurologic thromboembolic event 6. Contraindication to, or unwillingness to use systemic anticoagulation. 7. Subjects with contraindications or not tolerate to EP procedure, general anaesthesia, or the tests included in the study, like CPET, MRI. 8. Subjects cannot be removed from Class I/III AAD for reasons other than atrial arrhythmia. 9. Women of childbearing potential who are pregnant or lactating. 10. Renal insufficiency if an eGFR is \< 30 mL/min/1.73 m2, or with any history of renal dialysis or renal transplant. 11. Predicted life expectancy is less than 12 months.

Primary outcome measure(s)

Change in peak VO₂ from baseline to 6 months as assessed by CPET — 6 months
Change in peak oxygen uptake (peak VO₂) measured by cardiopulmonary exercise testing (CPET) at the 6-month visit compared with baseline.

Trial sites (1)

Facility	City	Region	Status
Sir Run Run Shaw Hospital	Hangzhou	Zhejiang

More Sir Run Run Shaw Hospital trials in China

Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer Starting soon

Evaluation of the Safety and Efficacy of a Wideband Electric Pulse Tumor Ablation System for Malignant Pulmonary Nodules Active, not recruiting

Effectiveness of Robotic Surgery for Right Colon Cancer Starting soon

The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT) Active, not recruiting

Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07453940 on ClinicalTrials.gov ↗ ← All trials in China